Thursday, October 06, 2022 8:33:11 AM
Excitement mounting for clinical stage neuroscience program in Kv7 Ion Channel Modulation which targets key subunits involved in neuronal signaling and plays a critical role in regulating the hyperexcitable state in epilepsy and potentially other central nervous system (CNS) disorders.
Biohaven retains Board and key management team with established legacy of bringing the market-leading medicine Nurtec® ODT (rimegepant) to patients; Names Bruce Car, Ph.D. as Chief Scientific Officer; Irfan Qureshi, M.D. as Chief Medical Officer; and Tanya Fischer, M.D., Ph.D. as Chief Development Officer and Head of Translational Medicine.
NEW HAVEN, Conn., Oct. 4, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders, leveraging its proven drug development capabilities and proprietary technology platforms to advance a pipeline of best-in-class therapies. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer in May 2022. The company, led by Vlad Coric, M.D. as Chairman and Chief Executive Officer, launched with approximately $257.8 million in cash at the distribution and no debt."
New York Yankees and Duke Basketball
Recent BHVN News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/09/2024 08:16:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:14:14 PM
- Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments • PR Newswire (US) • 05/09/2024 08:05:00 PM
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 04/22/2024 08:05:00 PM
- Biohaven Announces Proposed Public Offering of Common Shares • PR Newswire (US) • 04/17/2024 08:05:00 PM
- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates • PR Newswire (US) • 04/13/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:16:45 PM
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments • PR Newswire (US) • 02/29/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:30:54 PM
- Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncolo • PR Newswire (US) • 01/08/2024 12:30:00 PM
- Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/02/2024 12:00:00 PM
- Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting • PR Newswire (US) • 12/01/2023 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:15:28 PM
- Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments • PR Newswire (US) • 11/14/2023 09:05:00 PM
- Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® • PR Newswire (US) • 10/16/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:27 PM
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 10/05/2023 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/04/2023 08:05:45 PM
- Biohaven Announces Pricing of $225 Million Public Offering of Common Shares • PR Newswire (US) • 10/03/2023 03:56:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 01:41:44 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/02/2023 09:09:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/02/2023 09:07:23 PM
- BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES • PR Newswire (US) • 10/02/2023 08:36:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 10/02/2023 08:01:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 10:58:58 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM